1Cleator S,Heller W,Coombes RC.Triple-negative breast cancer:therapeutic options[J].Lancet Oncol,2007,8(3):235-244.
2Rakaha EA,EL-Sayed ME,Green AR,et al.Prognostic markers in triple-negative breast cancer[J].Cancer,2007,109(1):25-32.
3Perou CM,Sorlie T,Eisen MB,et al.Molecular portraits of human breast tumours[J].Nature,2000,406(6797):747-752.
4Nielsen TO,Hsu FD,Jensen K,et al.Immunohistochemicaland clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Res,2004,10(16):5367-5374.
5Srlie T,Perou CM,Tibshirani R,et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J].Proc Natl Aead Sci USA,2001,98(9):10869-10874.
6Van de Rijn M,Perou CM,Tibshirani R,et al.Expression of cytokeratins 17 and 5 identifies a group of breast carcinomaswith poor clinical outcome[J].Am J Pathol,2002,161(6):1991-1996.
7Turner N,Tutt A,Ashworth A.Hallmarks of 'BRCAness' in sporadic cancers[J].Nat Rev Cancer,2004,4(10):814-819.
8Turner NC,Reis-Filho JS.Basal-like breast cancer and the BRCA1 phenotype[J].Oncogene,2006,25 (43):5846-5853.
9Turner N,Tutt A,Ashworth A.Targeting the DNA repair defect of BRCA tumours[J].Curr Opin Pharmacol,2005,5(4):388-393.
10Quinn JE,Kennedy RD,Mullan PB,et al.BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis[J].Cancer Res,2003,63(19):6221-6228.
同被引文献15
1Perou CM,Sorlie T,Eisen MB,et al.Molecular portraits of human breast tumours. Nature . 2000
2Cleator S,Heller W,Coombes R C,et al.Triple-negative breast cancer: therapeutic options. Lancet Oncology,The . 2007
